Combination treatment for relapsed ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of drugs (adebrelimab, chemotherapy, bevacizumab, and fluzoparib) for ovarian cancer that has returned after a period of remission. It may help by using the immune system and targeted therapy to attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have ovarian, fallopian tube, or primary peritoneal cancer that has come back more than 6 months after finishing platinum-based chemotherapy.
- You must not have a BRCA gene mutation.
- You must have had no more than one previous PARP inhibitor treatment.
- You must be able to care for yourself and be up and about (ECOG score of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a combination of two drugs, adebrelimab and fuzuloparib, alongside chemotherapy for ovarian cancer that has returned within 6 months of platinum treatment. It aims to see if this combination can help control the cancer better than standard options.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests a new combination of drugs for ovarian cancer that has come back after responding to platinum chemotherapy. The goal is to see if adding these drugs helps control the cancer longer.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
Hear when a new Platinum-sensitive Relapsed Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.